Dr Georges F. Hatoum is the Medical Director of the JFK Comprehensive Cancer Institute. He obtained his medical degree with honors from the Lebanese University, Faculty of Medical Sciences. His residency was completed at the Syracuse Upstate Medical University with rotations at the University of Miami and Sloan-Kettering Cancer Center. He was then appointed as the Chief of Radiation Oncology at the Stratton VA Medical Center, Albany, NY where he carried an appointment as Assistant Professor of Medicine.
From 2006-2010, Dr Hatoum worked at the Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine. Dr Hatoum carried different appointments including Associate Professor of Clinical Radiation Oncology, co-leader of the head and neck cancer site disease group as well as Associate Director of Radiation Oncology at Jackson Memorial Hospital. During his professorship at the University of Miami, Dr Hatoum was chosen as the 2009 ARRO teacher of the year award winner, America's top Radiation Oncologists by the Research Council of America, as well as the Osler Institute award winner of Excellence in Teaching. He was also the local principal investigator for different RTOG as well as pharmaceutical trials.
Dr Hatoum joins JFK as the newly appointed Medical Director of Radiosurgery and Radiation Oncology. He also carries an appointment as an Affiliate Associate Professor of Clinical Biomedical Science at Charles E. Schmidt College of Medicine at FAU.
Books and monographs published:
1. Sagerman RH, Hatoum GF, Hahn SS. Optic Pathway Glioma. Radiotherapy of intraocular and orbital tumors. Springer, 2002: 137-144.
2. Hatoum GF, Wen B-C. Meningioma. In: Radiation Oncology: An Evidence-based Approach, Jiade J. Lu and Luther W. Brady Eds, Springer, 2008: 473-481.
3. Takita C, Hatoum GF. Pediatric Central Nervous System Tumors. In: Radiation Oncology: An Evidence-based Approach, Jiade J. Lu and Luther W. Brady Eds, 2008: 548-555.
Juried or refereed journal articles or exhibitions:
1. Hatoum GF, Nevaldine B., Bhavsar T., and Hahn P.J., Wr-1065, the active form of amifostine, protects hl-60 cells but not peripheral blood mononuclear cells from radiation and etoposide-induced apoptosis. International Journal of Radiation Oncology Biology Physics, (59): 844-851, 2004
2. Hatoum GF, Patton B, Takita C, Abdel-Wahab M, Lafave K, Weed D, Reis I . Small Cell Carcinoma of the Head and Neck: The University of Miami Experience, Int. J. Radiation Oncology Biol. Phys., 74(2):477-481, 2009
3. Hatoum GF, Abitbol A, Elattar I, and Abdel-Wahab M. Radiation Technique Influence on PEG Tube Dependence: Comparison between Two Radiation Schemes, Head and Neck, 31(7):944-948, 2009.
4. Bastos B, Hatoum GF, Raez LE, Waker G. Efficacy and Toxicity of Chemoradiotherapy with Carboplatin and Irinotecan Followed by Consolidation Docetaxel for Unresectable Stage III Non-small Cell Lung Cancer, Journal of Thoracic Oncology, 5(4):533-539, 2010
5. Neskey D, Hatoum G, et al. Outcomes after Surgical Resection of Head and Neck Paragangliomas, Skull Base 21(3): 171-176, 2011